GRAILGRAL

Key highlights

• One-time tax gain inflated profit: The reported net loss of $110.2 million was helped by a $56.5 million tax benefit, which is a one-time accounting gain that will not repeat. Without these special items, the company lost $90.3 million on an adjusted basis as it continues to spend heavily to launch its cancer screening technology.
• Galleri test volume growing: The company performed more than 61,000 Galleri tests during the quarter, a 35% increase from the same time last year. This growth shows steady adoption of the blood test, which can detect dozens of different cancers with a single draw.
• Clinical data showing utility: A major study of 140,000 people showed that using the Galleri test alongside standard screenings reduced late-stage diagnoses of aggressive cancers by up to 26% in later screening rounds. This supports the long-term case that the test can find cancers early enough to improve survival rates.
• Fresh cash from Samsung: The company completed a $110 million investment from Samsung to help fund operations and expand its reach into Asian markets. This capital helped bring the total cash balance to $861.6 million, providing a vital safety net while the business is still losing money.
• Fall FDA review ahead: Management expects the Food and Drug Administration to hold a public committee meeting this fall to review its application for full approval of the Galleri test. A positive outcome from this review is a necessary step for the test to be more widely covered by insurance and used across the United States.

Our take: This was a productive quarter where the business performed better than the headlines suggest. While the company is still losing significant money, the 35% jump in test volume and the $110 million cash infusion from Samsung keep the growth story on track while waiting for a critical FDA decision this fall.